Literature DB >> 32840681

Endovascular treatment of anterior cranial fossa dural arteriovenous fistula: a multicenter series.

Guilherme Dabus1,2, Peter Kan3, Carlos Diaz4, Boris Pabon5, Juan Andres-Mejia5, Italo Linfante6, Jonathan A Grossberg7, Brian M Howard7, Civan Islak8, Naci Kocer8, Osman Kizilkilic8, Ajit S Puri9, Anna L Kuhn9, Viraj Moholkar9, Santiago Ortega-Gutierrez10, Edgar A Samaniego10, Michael W McDermott6.   

Abstract

PURPOSE: We report a multicenter experience using endovascular embolization as the first line approach for treatment of anterior cranial fossa (ACF) dural arteriovenous fistula (DAVF).
METHODS: All patients with DAVFs located in the anterior cranial fossa who were treated with endovascular technique as a first line approach were included. Demographics, clinical presentation, angioarchitecture, strategy, complications, immediate angiographic, and follow-up results were included in the analysis.
RESULTS: Twenty-three patients met the inclusion criteria (18 male and 5 female). Age ranged from 14 to 79 years (mean 53 years). Twelve patients presented with hemorrhage. Twenty-eight endovascular procedures were performed. The overall immediate angiographic cure rate after endovascular treatment was 82.6% (19/23 patients). The angiographic cure rate of the transvenous strategy was significantly superior to the transarterial strategy (p ≤ 0.001). There was 1 complication in 28 total procedures (3.6%). Angiographic follow-up was available in 21 out of the 23 patients with a mean of 25 months (range 2 to 108 months). In these 21 patients, the DAVF was completely cured in 20 (95%). At last follow-up, all patients had a modified Rankin scale (mRS) 0 to 2.
CONCLUSION: Our experience suggests that endovascular treatment for ACF DAVFs has an acceptable safety profile with high rates of complete occlusion, particularly with transvenous approach. Whenever possible, transvenous approach should be preferred over transarterial approach as first line strategy.

Entities:  

Keywords:  Anterior cranial fossa; Dural arteriovenous fistula; Embolization; Endovascular; Ethmoidal; Transarterial; Transvenous

Year:  2020        PMID: 32840681     DOI: 10.1007/s00234-020-02536-3

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  2 in total

1.  Endovascular treatment of intracranial arteriovenous malformations with onyx: technical aspects.

Authors:  W Weber; B Kis; R Siekmann; D Kuehne
Journal:  AJNR Am J Neuroradiol       Date:  2007-02       Impact factor: 3.825

2.  Monorail snare technique for the retrieval of an adherent microcatheter from an onyx cast: technical case report.

Authors:  Michael E Kelly; Raymond Turner; Vivek Gonugunta; Peter A Rasmussen; Henry H Woo; David Fiorella
Journal:  Neurosurgery       Date:  2008-07       Impact factor: 4.654

  2 in total
  4 in total

Review 1.  Endovascular Management of Intracranial Dural AVFs: Transvenous Approach.

Authors:  K D Bhatia; H Lee; H Kortman; J Klostranec; W Guest; T Wälchli; I Radovanovic; T Krings; V M Pereira
Journal:  AJNR Am J Neuroradiol       Date:  2021-10-14       Impact factor: 3.825

2.  Endovascular embolization of high-grade cerebral dural arteriovenous fistulas - assessment of long-term recurrences.

Authors:  Alan Mendez-Ruiz; Waldo R Guerrero; Viktor Szeder; Mudassir Farooqui; Cynthia B Zevallos; Darko Quispe-Orozco; Santiago Ortega-Gutierrez
Journal:  Interv Neuroradiol       Date:  2021-09-13       Impact factor: 1.764

3.  Transarterial embolization through the infraorbital artery of the ethmoidal dural arteriovenous fistula causing recurrent epistaxis: illustrative case.

Authors:  Min-Yong Kwon; Sae Min Kwon; Chang-Hyun Kim; Chang-Young Lee
Journal:  J Neurosurg Case Lessons       Date:  2021-04-26

4.  Dural arteriovenous fistula with crista galli erosion in a patient with suspected sinusitis.

Authors:  Yuki Takaki; Satoshi Tsutsumi; Shinichiro Teramoto; Senshu Nonaka; Hidehiro Okura; Takamoto Suzuki; Hisato Ishii
Journal:  Radiol Case Rep       Date:  2021-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.